MISSISSAUGA, ON, Sept. 20 /PRNewswire-FirstCall/ - YM BioSciences Inc. , will release its fiscal 2007 financial results on Monday, September 24, 2007 at 1:00AM (EDT) (6:00AM BST). The announcement will be followed by a conference call at 9:00AM (EST), hosted by David Allan, Chairman, CEO & Director of YM BioSciences Inc.
CONFERENCE CALL DETAILS ----------------------- DATE: Monday, September 24th, 2007 TIME: 9:00 AM (EDT) DIAL IN NUMBER: 416-644 3414 or 1-800-733-7560 TAPED REPLAY: 416-640-1917 or 1-877-289-8525 PASSWORD: 21247767 followed by the number sign
A live audio webcast of the conference call will be available through www.ymbiosciences.com. Please connect to this website at least 15 minutes prior to the conference call to ensure adequate time for any software download that may be needed to hear the webcast. A replay of the webcast will be available for 90 days starting on September 24th, 2007 at www.ymbiosciences.com. A replay of the conference call will also be available by telephone on September 24th, 2007 through October 1st, 2007.
About YM BioSciences
YM BioSciences Inc. is an oncology company that identifies, develops and commercializes differentiated products for patients worldwide. The Company has two late-stage products: nimotuzumab, a humanized monoclonal antibody that targets the epidermal growth factor receptor (EGFR) and is approved in several countries for treatment of various types of head and neck cancer; and AeroLEF(TM), a proprietary, inhaled-delivery composition of free and liposome-encapsulated fentanyl in development for the treatment of moderate to severe pain, including cancer pain.
This press release may contain forward-looking statements, which reflect the Company's current expectation regarding future events. These forward-looking statements involve risks and uncertainties that may cause actual results, events or developments to be materially different from any future results, events or developments expressed or implied by such forward-looking statements. Such factors include, but are not limited to, changing market conditions, the successful and timely completion of clinical studies, the establishment of corporate alliances, the impact of competitive products and pricing, new product development, uncertainties related to the regulatory approval process and other risks detailed from time to time in the Company's ongoing quarterly and annual reporting. Certain of the assumptions made in preparing forward-looking statements include but are not limited to the following: that nimotuzumab will continue to demonstrate a competitive safety profile in ongoing and future clinical trials; that AeroLEF(TM) will continue to generate positive efficacy and safety data in future clinical trials; and that YM and its various partners will complete their respective clinical trials within the timelines communicated in this release. We undertake no obligation to publicly update or revise any forward-looking statements, whether as a result of new information, future events or otherwise.
YM BioSciences Inc.CONTACT: Thomas Fechtner, the Trout Group LLC, Tel. (212) 477-9007 x 31,Fax (212) 460-9028, Email: tfechtner@troutgroup.com; James Smith, theEquicom Group Inc., Tel. (416) 815-0700 x 229, Fax (416) 815-0080, Email:jsmith@equicomgroup.com; Nominated Adviser, Canaccord Adams Limited, RyanGaffney, Tel. +44 (0)20 7050 6500
